Contineum Therapeutics, Inc.
Income Statement
| Line Item | FY2024 | FY2023 |
|---|---|---|
| Revenue | $0 | $50.0M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $38.4M | $27.6M |
| SG&A Expense | $12.5M | $6.3M |
| Operating Income | $-50.9M | $16.1M |
| Operating Margin | — | 32.2% |
| Interest Expense | — | — |
| Pretax Income | $-42.3M | $23.2M |
| Income Tax Expense | $0 | $450.0K |
| Net Income | $-42.3M | $22.7M |
| Net Margin | — | 45.4% |
| EPS (Basic) | $-2.18 | $0.23 |
| EPS (Diluted) | $-2.18 | $0.01 |
| Shares Outstanding (Basic) | 19.4M | 13.9M |
| Shares Outstanding (Diluted) | 19.4M | 20.4M |
| Dividends Per Share | — | — |